Obesity is linked to disease severity in moderate to severe atopic dermatitis-Data from the prospective observational TREATgermany registry

Atopic Dermatitis

Targeted Combined Endpoint Improvement in Patient and Disease Domains in Atopic Dermatitis: A Treat-to-Target Analysis of Adults with Moderate-to-Severe Atopic Dermatitis Treated with Upadacitinib

Acta Derm Venereol

Kwatra SG, De Bruin-Weller M, Silverberg JI, Lio P, Deleuran M, Aydin H, Calimlim BM, Lane MC, Liu Y, Ofori S, Weidinger S

doi: 10.2340/actadv.v104.18452

Atopic Dermatitis

Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay Registry

J Am Acad Dermatol

Zhang J, Boesjes CM, Loman L, Kamphuis E, Romeijn MLE, Spekhorst LS, Haeck I, van der Gang LF, Dekkers CC, van der Rijst LP, Oosting AJ, van Lumig P, van Lynden-van Nes AMT, Tupker RA, Nijssen A, Flinterman A, Politiek K, Touwslager WRH, Christoffers WA, Stewart SM, Kamsteeg M, de Graaf M, de Bruin-Weller MS, Schuttelaar MA

doi: 10.1016/j.jaad.2024.04.026

Atopic Dermatitis

One-Year Insights into the GLOBOSTAD Multinational Prospective Observational Study of Patients Receiving Dupilumab for Atopic Dermatitis

Adv Ther

Calzavara-Pinton P, Chu CY, Lapeere H, Rossi M, Ferrucci SM, Chung WH, Fougerousse AC, Fomina DS, Holzer G, Čelakovská J, Al-Ahmad M, Tzellos T, Wu J, Ardeleanu M, Bosman K

doi: 10.1007/s12325-024-03049-8

Atopic Dermatitis

Drug utilization among young adults with atopic dermatitis: Influence of sex, socio-economic status and disease severity

J Eur Acad Dermatol Venereol

Carmanius PL, Lundin S, Ödling M, Kimland E, Ballardini N, Melén E, Bergström A, Dahlén E

doi: 10.1111/jdv.20076

Atopic Dermatitis

Cendakimab in Patients With Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial

JAMA Dermatol

Blauvelt A, Guttman-Yassky E, Lynde C, Khattri S, Schlessinger J, Imafuku S, Tada Y, Morita A, Wiseman M, Kwiek B, Machkova M, Zhang P, Linaberry M, Li J, Zhang S, Franchin G, Charles ED, De Oliveira CHMC, Silverberg JI

doi: 10.1001/jamadermatol.2024.2131

Atopic Dermatitis

Dupilumab in Adults With Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension Study

JAMA Dermatol

Beck LA, Bissonnette R, Deleuran M, Nakahara T, Galus R, Coleman A, Gherardi G, Xiao J, Dingman R, Xu C, Avetisova E, Dubost-Brama A, Shabbir A

doi: 10.1001/jamadermatol.2024.1536

Atopic Dermatitis

Upadacitinib in Adolescents With Moderate to Severe Atopic Dermatitis: Analysis of 3 Phase 3 Randomized Clinical Trials Through 76 Weeks

JAMA Dermatol

Paller AS, Mendes-Bastos P, Siegfried E, Eichenfield LF, Soong W, Prajapati VH, Lio P, Simpson EL, Raymundo EM, Suravaram S, Hu X, Yang Y, Huang X, Calimlim BM, Platt AM, Su JC, Zheng M, Yamamoto-Hanada K, Teixeira HD, Irvine AD

doi: 10.1001/jamadermatol.2024.3696

Atopic Dermatitis

Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials

Lancet

Silverberg JI, Wollenberg A, Reich A, Thaçi D, Legat FJ, Papp KA, Stein Gold L, Bouaziz JD, Pink AE, Carrascosa JM, Rewerska B, Szepietowski JC, Krasowska D, Havlíčková B, Kalowska M, Magnolo N, Pauser S, Nami N, Sauder MB, Jain V, Padlewska K, Cheong SY, Fleuranceau Morel P, Ulianov L, Piketty C, ARCADIA 1 and ARCADIA 2 Study Investigators

doi: 10.1016/S0140-6736(24)01203-0

Allergic Diseases

Allergic contact dermatitis in adults with and without atopic dermatitis: Evaluation of the Spanish Contact Dermatitis Registry (REIDAC)

Contact Dermatitis

Chicharro P, Munera-Campos M, Zaragoza-Ninet V, Giménez-Arnau A, González-Pérez R, Miquel-Miquel FJ, Córdoba-Guijarro S, Sanz-Sánchez T, Ruiz-González I, Silvestre-Salvador JF, Serra-Baldrich E, Borrego L, Pastor-Nieto MA, Ortiz de Frutos FJ, Mercader-García P, Heras-Mendaza F, Fernández-Redondo V, Rodríguez-Serna M, Hervella-García M, Carrascosa JM, Gallego-Descalzo MA, García-Doval I, Sánchez-Pérez J

doi: 10.1111/cod.14672

Related content

Targeted Combined Endpoint Improvement in Patient and Disease Domains in Atopic Dermatitis: A Treat-to-Target Analysis of Adults with Moderate-to-Severe Atopic Dermatitis Treated with Upadacitinib

Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay Registry

One-Year Insights into the GLOBOSTAD Multinational Prospective Observational Study of Patients Receiving Dupilumab for Atopic Dermatitis

Drug utilization among young adults with atopic dermatitis: Influence of sex, socio-economic status and disease severity

Cendakimab in Patients With Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial

Dupilumab in Adults With Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension Study

Upadacitinib in Adolescents With Moderate to Severe Atopic Dermatitis: Analysis of 3 Phase 3 Randomized Clinical Trials Through 76 Weeks

Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials

Allergic contact dermatitis in adults with and without atopic dermatitis: Evaluation of the Spanish Contact Dermatitis Registry (REIDAC)